OBJECTIVES: A randomized, double-blind, placebo-controlled trial (RCT) of herpes simplex virus type 2 suppressive therapy with acyclovir 400 mg twice daily conducted among women in northwestern Tanzania reported a similar rate of HIV acquisition in both trial arms (Current Controlled Trials number ISRCTN35385041). Risk factors for HIV incidence were examined in the context of 3-monthly follow-up visits offering both voluntary counselling and testing and care for sexually transmitted infections. DESIGN: Prospective cohort analysis of trial participants enrolled and followed for up to 30 months. METHODS: Risk factors for HIV acquisition were analysed using Cox regression. RESULTS: Overall, 821 herpes simplex virus type 2 seropositive, HIV seronegative women were randomized; 400 randomized to acyclovir and 421 to placebo; 659 (80.3%) completed follow-up. HIV incidence was 4.27 per 100 person-years. There was no overall impact of acyclovir on HIV incidence [hazard ratio = 1.01; 95% confidence interval (CI) 0.61-1.66]. HIV acquisition was independently associated with younger age at enrolment (age 16-19 vs. 30-35: hazard ratio = 4.02; 95% CI 1.67-9.68), alcohol consumption at enrolment (> or =30 drinks/week vs. none: hazard ratio = 4.39, 95% CI 1.70-11.33), having paid sex within the previous 3 months (hazard ratio = 1.82, 95% CI 1.09-3.05), recent infection with gonorrhoea (hazard ratio = 3.62, 95% CI 1.62-8.08) and injections in the previous 3 months (hazard ratio = 3.45, 95% CI 1.62-7.34). There was some evidence of an association between HIV incidence and living in the recruitment community for less than 2 years (hazard ratio = 1.75, 95% CI 0.98-3.10) and exposure to hormonal contraception (hazard ratio = 1.60, 95% CI 0.93-2.76). CONCLUSION: A high incidence of HIV was observed in this trial cohort, especially in young women. Interventions are needed to address the risk associated with alcohol use and to sustain control of other sexually transmitted infections.
OBJECTIVES: A randomized, double-blind, placebo-controlled trial (RCT) of herpes simplex virus type 2 suppressive therapy with acyclovir 400 mg twice daily conducted among women in northwestern Tanzania reported a similar rate of HIV acquisition in both trial arms (Current Controlled Trials number ISRCTN35385041). Risk factors for HIV incidence were examined in the context of 3-monthly follow-up visits offering both voluntary counselling and testing and care for sexually transmitted infections. DESIGN: Prospective cohort analysis of trial participants enrolled and followed for up to 30 months. METHODS: Risk factors for HIV acquisition were analysed using Cox regression. RESULTS: Overall, 821 herpes simplex virus type 2 seropositive, HIV seronegative women were randomized; 400 randomized to acyclovir and 421 to placebo; 659 (80.3%) completed follow-up. HIV incidence was 4.27 per 100 person-years. There was no overall impact of acyclovir on HIV incidence [hazard ratio = 1.01; 95% confidence interval (CI) 0.61-1.66]. HIV acquisition was independently associated with younger age at enrolment (age 16-19 vs. 30-35: hazard ratio = 4.02; 95% CI 1.67-9.68), alcohol consumption at enrolment (> or =30 drinks/week vs. none: hazard ratio = 4.39, 95% CI 1.70-11.33), having paid sex within the previous 3 months (hazard ratio = 1.82, 95% CI 1.09-3.05), recent infection with gonorrhoea (hazard ratio = 3.62, 95% CI 1.62-8.08) and injections in the previous 3 months (hazard ratio = 3.45, 95% CI 1.62-7.34). There was some evidence of an association between HIV incidence and living in the recruitment community for less than 2 years (hazard ratio = 1.75, 95% CI 0.98-3.10) and exposure to hormonal contraception (hazard ratio = 1.60, 95% CI 0.93-2.76). CONCLUSION: A high incidence of HIV was observed in this trial cohort, especially in young women. Interventions are needed to address the risk associated with alcohol use and to sustain control of other sexually transmitted infections.
Authors: K Fonck; R Kaul; J Kimani; F Keli; K S MacDonald; A R Ronald; F A Plummer; P Kirui; J J Bwayo; E N Ngugi; S Moses; M Temmerman Journal: Int J STD AIDS Date: 2000-12 Impact factor: 1.359
Authors: Joseph K B Matovu; Ronald H Gray; Fredrick Makumbi; Maria J Wawer; David Serwadda; Godfrey Kigozi; Nelson K Sewankambo; Fred Nalugoda Journal: AIDS Date: 2005-03-25 Impact factor: 4.177
Authors: Barbara Van Der Pol; Cynthia Kwok; Bosny Pierre-Louis; Anne Rinaldi; Robert A Salata; Pai-Lien Chen; Janneke van de Wijgert; Francis Mmiro; Roy Mugerwa; Tsungai Chipato; Charles S Morrison Journal: J Infect Dis Date: 2008-02-15 Impact factor: 5.226
Authors: Richard G White; S Cooper Ben; Anusha Kedhar; Kate K Orroth; Sam Biraro; Rebecca F Baggaley; Jimmy Whitworth; Eline L Korenromp; Azra Ghani; Marie-Claude Boily; Richard J Hayes Journal: Proc Natl Acad Sci U S A Date: 2007-05-23 Impact factor: 11.205
Authors: Steffen Geis; Leonard Maboko; Elmar Saathoff; Oliver Hoffmann; Christof Geldmacher; Donan Mmbando; Eleuter Samky; Nelson L Michael; Deborah L Birx; Merlin L Robb; Michael Hoelscher Journal: J Acquir Immune Defic Syndr Date: 2011-04-15 Impact factor: 3.731
Authors: Adriana Weinberg; Amanda A Allshouse; Samantha Mawhinney; Jennifer Canniff; Lorie Benning; Eryka L Wentz; Howard Minkoff; Mary Young; Marek Nowicki; Ruth Greenblatt; Mardge H Cohen; Elizabeth T Golub Journal: J Acquir Immune Defic Syndr Date: 2012-05-01 Impact factor: 3.731
Authors: Adriana Weinberg; Jeong-Gun Park; Ronald Bosch; Alice Cho; Elizabeth Livingston; Fran Aweeka; Yoninah Cramer; D Heather Watts; Amneris E Luque; Susan E Cohn Journal: J Acquir Immune Defic Syndr Date: 2016-02-01 Impact factor: 3.731
Authors: Aderonke Odutola; Kathy Baisley; Richard J Hayes; Mary Rusizoka; Clare Tanton; Helen A Weiss; John Changalucha; David A Ross; Deborah Watson-Jones Journal: Sex Transm Infect Date: 2012-03-21 Impact factor: 3.519
Authors: Pauli N Amornkul; Hilde Vandenhoudt; Peter Nasokho; Frank Odhiambo; Dufton Mwaengo; Allen Hightower; Anne Buvé; Ambrose Misore; John Vulule; Charles Vitek; Judith Glynn; Alan Greenberg; Laurence Slutsker; Kevin M De Cock Journal: PLoS One Date: 2009-07-31 Impact factor: 3.240